{"title":"2022年5月至6月，6种药物面临关键专利到期和潜在仿制药上市。","authors":"Yali Friedman","doi":"10.4155/ppa-2022-0018","DOIUrl":null,"url":null,"abstract":"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 4","pages":"127-129"},"PeriodicalIF":1.8000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Six drugs facing key patent expirations and potential generic entry from May to June 2022.\",\"authors\":\"Yali Friedman\",\"doi\":\"10.4155/ppa-2022-0018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.</p>\",\"PeriodicalId\":20011,\"journal\":{\"name\":\"Pharmaceutical patent analyst\",\"volume\":\"11 4\",\"pages\":\"127-129\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical patent analyst\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4155/ppa-2022-0018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2022-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Six drugs facing key patent expirations and potential generic entry from May to June 2022.
A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
